

CONTENTS

Preface	xv
Contributors	xvii
PART I STUDIES OF NATURALLY OCCURRING PEPTIDES	1
1 Analysis of the Peptidomes of Amphibian Skin Granular Gland Secretions—An Integrated Functional Genomic Strategy	3
<i>Chris Shaw and Tianbao Chen</i>	
1.1 Introduction	3
1.2 Historical Perspective	5
1.3 Contemporary Methods of Sample Acquisition	6
1.4 The Integrated Functional Genomic Strategy	7
1.5 How then can All Three Approaches be Integrated?	8
1.6 Limitations of Each Approach	18
1.7 Closing Thoughts	19
2 A Short History of Insect (Neuro)Peptidomics—A Personal Story of the Birth and Youth of an Excellent Model For Studying Peptidome Biology	25
<i>Peter D.E.M. Verhaert, Martijn W.H. Pinkse, Maria C. Prieto-Conaway, and Markus Kellmann</i>	
2.1 Introduction	25

2.2	History	29
2.3	Present (and Future): Novel Technologies, New Data. . .	31
2.3.1	MALDI and (Nano)ESI TOFs and QTOFs	31
2.3.2	Peptide Displays	31
2.3.3	Ion Traps and FT-ICRs: Greater Variety of Instruments, Greater Variety of Sequences. . .	35
2.3.4	Orbitrap	35
2.3.5	FT-ICRs	40
2.3.6	Combining Peptide Chemical Analysis with Histological Localization: Peptidome Mass Spectrometry Imaging	42
2.4	Concluding Remarks	45
3	Peptidomics of Short Linear Cytolytic Peptides from Spider Venom	55
	<i>Sergey A. Kozlov, Alexander A. Vassilevski, and Eugene V. Grishin</i>	
3.1	Introduction	55
3.2	Peptidomics: Identifying and Sequencing Novel AMPs	57
3.3	Genomics: Unraveling the Biosynthetic Pathway	60
3.4	Venomomics: AMPs in the Spider Venom	64
3.4.1	Structural Features	65
3.4.2	Functional Features	65
3.4.3	Venomic Significance	66
4	Molecular Cloning Approaches to Peptidomics: The Identification of Novel cDNAs Encoding Neurotoxin-like Peptide Pools	71
	<i>Zhensheng Pan, Richard Barry, and Mikhail Soloviev</i>	
4.1	Introduction	71
4.2	Spider Toxins—Combinatorial Peptide Libraries	73
4.3	EST Cloning Approach to Cloning Peptide Families	74
4.4	PCR-Based Amplification and Cloning Approaches	74
4.5	The Design and Use of Hybrid Primers for the Amplification of cDNAs Coding for Large Toxin-like Peptide Pools	77
4.5.1	Multiple Alignment of the Existing Toxins and Toxin-like Sequences	77
4.5.2	The Design of Hybrid Partially Degenerate Primers	79
4.5.2.1	The Design of the 3' Region	79
4.5.2.2	The Design of the 5' Region and the Middle Part of the Primers	79
4.5.2.3	The Overall Length and Degeneracy	79
4.5.2.4	Annealing Temperature Matching	80
4.5.3	Optimization of the Amplification Conditions	82
4.5.4	Other Experimental Details	84
4.5.5	High Throughput Amplification and Cloning	85
4.5.6	Sequences Identification and Analysis	86

4.6	Polypeptide Toxins—Novel Applications in Drug and Pesticide Development	88
4.6.1	Analgesic Drugs	88
4.6.2	Insecticides	89
4.7	Concluding Remarks	91
4.7.1	RACE-PCR Issues	91
4.7.2	Sequence Quality Issues	91
4.7.3	Conclusion	92
5	Wheat Antimicrobial Peptides	99
	<i>Tatyana I. Odintsova and Tsezi A. Egorov</i>	
5.1	Introduction	99
5.2	Materials and Methods	101
5.2.1	Isolation of AMPs	101
5.2.2	Reduction and Alkylation of Peptides [35]	102
5.2.3	MALDI-TOF MS	102
5.2.4	High-Resolution Two-Dimensional Gel Electrophoresis	103
5.3	Isolation of AMPs from <i>T. kiharae</i> Seeds	103
5.4	Sequence Determination of AMPs from <i>T. kiharae</i> Seeds	106
5.5	Comparative Analysis of D Defensins from <i>Triticum</i> and <i>Aegilops</i> Species	111
5.6	Discussion	112
5.7	Concluding Remarks	115
6	Immunopeptidomics: Applications to Dissect Immune Responses Through Proteomic-based Approaches	119
	<i>Ernesto Oviedo-Orta and Alexandra Bermudez-Fajardo</i>	
6.1	Introduction	119
6.1.1	Innate Immune Responses	120
6.1.2	Adaptive Immune Responses	120
6.2	Naturally Occurring Peptides and MHC-I Molecules: Role in Immune Surveillance and Tolerance	121
6.2.1	Structure and Basic Function of MHC-I Molecules	121
6.2.2	Relationship Between Naturally Occurring Peptides and MHC-I Function: A Peptidomics Approach	122
6.2.2.1	Peptide Analogs as Useful Tools to Dissect Immunological Mechanisms	124
6.2.2.2	Synthetic Peptide Libraries	126
6.3	Presentation of Naturally Processed Peptide Antigens by MHC-II Molecules	126
6.3.1	Peptidomics Characterization of MHC-II-Binding Naturally Occurring Peptides	127

6.3.2	Functional Relationship Between MHC-II Molecules and Naturally Binding Peptides	128
6.4	Current Methodologies Applied to Peptidomics Analysis and the Identification of Naturally Processed Peptides	129
6.5	Potential Clinical Applications of Immunopeptidomic Analyses	132
7	Strategies for Reliable and Improved Identification of Peptides	139
	<i>Karl Sköld, Maria Fälth, Marcus Svensson, Anna Nilsson, Per Svenningsson, and Per E. Andrén</i>	
7.1	Introduction	139
7.2	Neuropeptides and Hormones	140
7.3	Identification of Neuropeptides	142
7.4	Improved Identification of Peptides Using SwePep	143
7.5	Differential Display of Peptides	144
7.6	Differential Display of Peptides in Models of Parkinson's Disease	147
	PART II PEPTIDOMICS METHODS AND NEW DEVELOPMENTS	153
8	Peptidomics Approach to Proteomics	155
	<i>Petra Zürbig and Harald Mischak</i>	
8.1	Introduction	155
8.2	Peptidomics Relating to Proteomics	156
	8.2.1 Definition of Peptides Versus Proteins	156
	8.2.2 Proteases—Producers of Peptides	157
8.3	Proteomics/Peptidomics	158
	8.3.1 Background on Proteomics	158
	8.3.2 General Objectives of Proteomics	158
	8.3.3 Peptidomics	160
8.4	The 'omics Technologies	161
	8.4.1 General Remarks	161
	8.4.2 Sample Preparation	161
	8.4.3 Basics of Mass Spectrometry	162
	8.4.4 Bottom-Up Versus Top-Down Approaches	166
	8.4.5 Separation Technologies Coupled MS	167
	8.4.5.1 Two-Dimensional Gel Electrophoresis Followed by Mass Spectrometry (2DE-MS)	167
	8.4.5.2 Liquid Chromatography Coupled to Mass Spectrometry (LC-MS)	169
	8.4.5.3 Surface-Enhanced Laser Desorption/Ionization Coupled to Mass Spectrometry (SELDI-MS)	169
	8.4.5.4 Capillary Electrophoresis Coupled to Mass Spectrometry (CE-MS)	170

8.4.6	Protein Arrays	170
8.5	Peptidomics Approach to Proteomics	171
9	The Importance of Sample Handling in Neuropeptidomics	177
	<i>Karl Sköld, Marcus Svensson, Anna Nilsson, Maria Fälth, Per Svenningsson, and Per Andréén</i>	
9.1	Introduction	177
9.2	Issues Using Postmortem Brain Tissue	178
9.3	Enzyme Inactivation Methods	179
9.3.1	Denaturation	179
9.3.2	Thermal Denaturation	179
9.3.3	Proteomics Denaturation Methods	179
9.3.4	Other Inactivation Methods	180
9.3.5	Protease Inhibitors	180
9.4	Brain Sample Preparation	181
9.5	Reliable Identification of Peptides in the Brain	181
9.6	Postmortem Time Effects on Peptides and Proteins	184
9.7	Protein Fragments as Degradation Markers	186
10	Affinity Peptidomics Approach to Protein Detection, Quantification, and Protein Affinity Assays: Application to Forensics and Biometrics	191
	<i>Julian Bailes and Mikhail Soloviev</i>	
10.1	Introduction	191
10.1.1	Protein and Peptides: Separation, Staining, and Detection	192
10.1.2	Affinity-Based Assays and Hardware Realizations	194
10.1.3	Micro-/Macroarray-Based Protein Assays	196
10.2	Peptidomics Approach to Affinity Assays	198
10.3	Forensic and Biometrics Marker Proteins and Peptide Selection	206
10.4	Protein Markers and Peptide Selection	208
10.4.1	Myoglobin (MG)	210
10.4.2	Tumor Necrosis Factor-Alpha (TNF- α)	211
10.4.3	Fibrinogen (Fb)/D-Dimer	211
10.4.4	C-Reactive Protein (CRP)	211
10.4.5	Interferon(s) (IFN)	212
10.4.6	Interleukin(s) (IL)	213
10.4.6.1	IL-1	213
10.4.6.2	IL-2	213
10.4.6.3	IL-4	213
10.4.6.4	IL-6	213
10.4.6.5	IL-8	214
10.4.6.6	IL-10	214
10.4.7	Beta-Enolase (β E)	214
10.4.8	E-Selectin (ES)	215
10.4.9	Fibronectin (FN)	215

10.4.10	Haptoglobin (HG)	215
10.4.11	Heat Shock Protein(s) (HSP)	216
10.4.12	Insulin-like Growth Factor-1 (IGF-1)	216
10.4.13	Leptin (Lp)	217
10.4.14	Prolactin (Prl)	217
10.4.15	Transforming Growth Factor-Beta (TGF- β)	217
10.4.16	Adiponectin (Adn)	218
10.4.17	Insulin (In)	218
10.4.18	Matrix Metalloproteinases (MMPs 1, 2, 3, 9, 11)	218
10.4.19	Prostate-Specific Antigen (PSA)	219
10.4.20	Serum Amyloid-A (SAA)	219
10.4.21	Sex-Hormone-Binding Globulin (SHBG)	220
10.4.22	Surfactant-Associated Protein A (SP-A)	221
10.5	Concluding Remarks	224
11	Selective Depletion and Enrichment Methods for the Analysis of Protein and Peptide Pools	233
	<i>Paul Finch and Mikhail Soloviev</i>	
11.1	Introduction	233
11.2	Peptide Mixture Refinement—General Approach to Combinatorial Peptidomics	239
11.3	Chemistry and Materials for Selective Reaction of Unmodified Amino Acid Side Chains	247
11.4	Selective Enrichment of Posttranslationally Modified Amino Acids	255
11.4.1	Phosphorylated Amino Acids	255
11.4.2	Selective Collection of Glycosylated Peptides	256
11.4.2.1	Phenyl Boronate Resins	258
11.4.2.2	Lectins	258
11.4.3	Amino Acids Modified by Covalent Attachment of Lipid Groups	258
11.5	Concluding Remarks	260
12	Detection of Target Peptides in Foods and Feeds by Mass Spectrometry	265
	<i>Mireia Fernández Ocaña</i>	
12.1	General Introduction	265
12.2	Introduction to GM Crops	266
12.3	Food Safety and Consumers Concerns	268
12.4	Current Detection Techniques of GM Material	268
12.5	Feed Contamination with Animal Protein in the Context of BSE and Control Measures	271
12.6	Plant Proteomics	272
12.7	Food Proteomics	274
12.8	Proteomic Investigations for the Detection of GM Crops	274

12.9	Case Study: Herbicide-Resistant GM Crops	275
12.9.1	Identification of CP4 EPSPS Peptides as Markers for Herbicide-Resistant GM Maize	275
12.9.2	Differential Protein Expression in GM and Non-GM Soya	277
12.10	Case Study: Gelatine Peptides as Markers for Contamination with Animal Protein	283
12.11	Concluding Remarks	287
13	Quantification of Polypeptides by Mass Spectrometry	291
	<i>Pedro R. Cutillas</i>	
13.1	Introduction	291
13.2	Development of Quantitative Mass Spectrometry for Polypeptide Analysis	293
13.3	Absolute Quantification of Polypeptides by Mass Spectrometry	295
13.3.1	The External Standard Method	295
13.3.2	The Internal Standard Method	297
13.4	Relative Quantification of Polypeptides by Mass Spectrometry	301
13.4.1	Methods Based on Derivatization	302
13.4.2	Methods Based on Metabolic Labeling	306
13.4.3	Label-Free Methods	307
13.5	Conclusions and Perspectives	311
	PART III PEPTIDOMICS APPROACH TO BIOMARKER DISCOVERY	317
14	Biomarker Discovery	319
	<i>Petra Zürbig and Harald Mischak</i>	
14.1	Introduction	319
14.2	Definition of Biomarkers	320
14.3	Biomarkers as Health Care Devices	321
14.4	Biomarker Discovery	323
14.5	Proteomic and Peptidomic Biomarker Research	323
14.6	Clinical Proteomics/Peptidomics	324
14.6.1	Single Biomarker Versus “Marker Pattern”	326
14.6.2	Clinical Application	327
14.7	CE–MS in Clinical Diagnosis	327
14.7.1	Selection of Source	327
14.7.2	Biomarkers from Blood, Dialysis Fluid, and Cerebrospinal Fluid	330
14.7.3	Urinary Biomarkers	332
14.7.4	Biomarker Identification by MS/MS Sequencing	334
14.8	Concluding Remarks	336

15 Can Peptidomics Provide a Useful Approach for the Identification of Biomarkers of Toxicological Exposure or Effect?	341
<i>Helen Griffiths</i>	
15.1 Introduction	341
15.2 Altered Peptide Expression and Secretion Profiles After Exposure to Stress or Toxins in Target Organs	344
15.3 Can Peptidomics Contribute to the Discovery of Biomarkers of Target Organ-Specific Toxin Exposure or Stress?	344
15.3.1 Evidence for Altered Peptide Profiles in Hepatotoxicity	345
15.3.2 Evidence for Altered Peptide Profiles in Nephrotoxicity	346
15.4 Proteolysis During Cytotoxicity	347
15.5 Alterations in Inflammatory Peptides Following Drug/Chemical Induced Toxicity	349
15.6 Concluding Remarks	351
16 Peptidomics in Neuroendocrine Research: A <i>Caenorhabditis elegans</i> and <i>Mus musculus</i> Study	355
<i>Kurt Boonen, Steven J. Husson, Geert Baggerman, Anja Cerstiaens, Walter Luyten, and Liliane Schoofs</i>	
16.1 Introduction	355
16.2 Methods	358
16.2.1 Extraction of Peptides	358
16.2.2 Dissection	358
16.2.3 Sample Preparation	359
16.2.4 HPLC	360
16.2.4.1 1D Nano-LC	360
16.2.4.2 2D Nano-LC	360
16.2.4.3 Online 2D Nano-LC	360
16.2.4.4 Off-line 2D Nano-LC	361
16.2.5 Mass Spectrometry	361
16.2.5.1 ESI QTOF Mass Spectrometry	361
16.2.5.2 Gas-Phase Fragmentation	364
16.2.5.3 MALDI-TOF Mass Spectrometry	364
16.2.6 Peptide Identification	364
16.2.6.1 Mascot Search	364
16.2.6.2 De Novo Sequencing	365
16.2.7 Neuropeptide Databases	365
16.3 Case Study 1: Peptidomics of <i>C. elegans</i>	367
16.3.1 Introduction	367
16.3.2 Bioinformatics: Prediction of Neuropeptide Genes	367
16.3.3 Biochemical Characterization of Neuropeptides	368
16.3.4 Experimental Procedures	368
16.3.4.1 Sample Preparation	368
16.3.4.2 Peptide Identification	368

CONTENTS	xiii
16.3.5 Results	369
16.3.5.1 Identification of 60 Endogenous Peptides by Online 2D Nano-LC QTOF MS/MS	369
16.3.5.2 Identification of 75 Neuropeptides by Off-Line HPLC MALDI-TOF MS	369
16.3.5.3 Differential Peptidomic Analysis of <i>C. elegans</i> Strains	372
16.3.6 Conclusions	372
16.4 Case Study 2: Peptidomics of the Murine Pituitary Gland	374
16.4.1 Introduction	374
16.4.2 Experimental Procedures	375
16.4.2.1 Peptide Extraction	375
16.4.2.2 Peptide Identification	375
16.4.3 Results	375
16.4.3.1 Proopiomelanocortin (POMC)	376
16.4.3.2 Secretogranin I (Chromogranin B)	376
16.4.3.3 Secretogranin II	376
16.4.3.4 Secretogranin III	380
16.4.3.5 Chromogranin A	380
16.4.3.6 Neuroendocrine Secretory Protein 55 (NESP55)	380
16.4.3.7 Neurosecretory Protein 7B2	380
16.4.3.8 ProSAAS	380
16.4.3.9 Oxytocin Precursor	380
16.4.3.10 Vasopressin–Neurophysin 2–Copeptin Precursor	381
16.4.3.11 Peptidyl-Glycine α -Amidating Monooxygenase Precursor	381
16.4.3.12 Cystatin C	381
16.4.4 Discussion	381
16.5 General Conclusion	383
PART IV CONCLUSION	387
17 Peptidomics and Biology: Two Scientific Disciplines Driving Each Other	389
<i>Chris Shaw and Peter D.E.M. Verhaert</i>	
Index	397

